This is the authors' abstract. We don't add key points for this paper.
Abstract Background: The multiscale quantitative systems pharmacology (QSP) model, which includes biomolecule, cellular and tissue data, was used for the preclinical to clinical translation of ADC efficacy. Here, we validated the feasibility of the model using the marketed drug disitamab vedotin (DV). Methods: Model integrated pharmacokinetics (PK), in vitro tumor cell disposition data and tumor growth inhibition (TGI) data were obtained. This mechanistically explains how the ADC exerted efficacy. Based on the in vivo efficacy data, which were obtained from studies conducted using two cell-derived xenograft models (NCI-N87 and SKOV3), a QSP model was established to characterize the efficacy, and the inherent sensitivity of the ADC between patient populations with different target expression levels was further simulated. For preclinical to clinical transitioning, human PK behavior was predicted with allometric scaling using the data of the monkeys’ PK parameters. Key parameters impacting the QSP model, such as TGI, tumor volume, and target expression level of tumors, were replaced with clinically relevant data to predict the effective dose of DV in patients. The clinically approved Q2W dosing intervals were used to simulate the effective dose. Results: After continuous administration of 1.5-2 mg/kg Q2W for five months, patients with HER2-2+ and HER2-3+ tumors achieved an objective response rate (ORR), but progressive disease was observed in HER2-1+ patients, which was consistent with clinically observed efficacy outcomes. Conclusions: The model has promising applications in ADC screening, the optimization of clinical dosing regimens and other related areas.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Li et al. (2024) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: